

ASX Announcement

23 July 2025

Completion of Recruitment in TRIPP-FFX Clinical Trial

Key Highlights:

- Patient recruitment for the TRIPP-FFX clinical trial has now been successfully completed.
- This study represents an important part of OncoSil Medical's well-articulated clinical development strategy.
- The primary objective of the TRIPP-FFX trial is to evaluate the safety and efficacy of the OncoSil™ device when used in addition to FOLFIRINOX chemotherapy.
- OncoSil Medical expects data from the TRIPP-FFX study to become available in early calendar 2026.

Sydney, Australia – 23 July 2025: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** ("**OncoSil**" or "**the Company**") is pleased to announce the successful completion of patient recruitment for the TRIPP-FFX clinical trial.

OncoSil™ device's clinical development accelerated by TRIPP-FFX study

The TRIPP-FFX study is a prospective, multi-centre clinical trial evaluating the safety and efficacy of the OncoSil™ device when used in addition to FOLFIRINOX chemotherapy in patients with locally advanced pancreatic cancer (LAPC). This study, like the PANCOSIL Investigator Initiated Study which also recently met its patient recruitment target, is an important part of the Company's well-articulated clinical development strategy for the OncoSil™ device.

At least 88 patients have been recruited into the TRIPP-FFX study across 15 leading hospitals located in Europe and Australia. The completion of recruitment for the TRIPP-FFX study marks a major milestone in the OncoSil™ device's development journey. The study forms part of OncoSil's sustained efforts to build the clinical evidence base needed to support the broader adoption of the OncoSil™ device in addition to standard-of-care chemotherapy. The study has attracted strong interest from clinicians and patients across participating sites in Europe and Australia, resulting in an acceleration of patient recruitment over the past few months.

OncoSil Medical expects data from the TRIPP-FFX study to become available in early calendar 2026.

Giuseppe Malleo, One of the two Coordinating Investigators of the TRIPP-FFX study and Associate Professor of Surgery at the University of Verona, said:

"The TRIPP-FFX study represents an important step in exploring new therapeutic options for patients with locally advanced pancreatic cancer. The integration of the OncoSil™ device with FOLFIRINOX chemotherapy could offer a meaningful improvement in clinical outcomes. We are pleased to have completed recruitment and look forward to analysing the results."

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"We are thrilled by the speed at which patient recruitment for the TRIPP-FFX clinical trial has occurred. It means that yet another milestone in our well-articulated clinical development strategy for the OncoSil™ device has been met. I personally want to thank our clinical partners for their sustained efforts to deliver the study's target patient recruitment level. Because of their hard work and dedication, the strong momentum behind OncoSil Medical team's commitment to demonstrate the multiple ways its innovative treatment platform will continue to occur at a rapid pace. We now look forward to the data readout from the study. In the meantime, we will strive to realise other development and commercialisation milestones for the OncoSil™ device, which is improving outcomes for patients with unresectable locally advanced pancreatic cancer."

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Nathan Jong Company Secretary E: Nathan.Jong@acclime.com T: +61 3 9864 4810	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	--	---

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Türkiye, and Israel.

To learn more, please visit: www.oncosil.com/

References: <https://gco.iarc.fr/en>